4.8 Editorial Material

Mutation signature of adenoid cystic carcinoma: evidence for transcriptional and epigenetic reprogramming

Journal

JOURNAL OF CLINICAL INVESTIGATION
Volume 123, Issue 7, Pages 2783-2785

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI69070

Keywords

-

Funding

  1. NCI NIH HHS [P30 CA044579] Funding Source: Medline
  2. NIDCR NIH HHS [RC1-DE020687, RC1 DE020687, RFP NHLBI-DE-09-10] Funding Source: Medline

Ask authors/readers for more resources

Adenoid cystic carcinoma (ACC), a relatively rare malignancy usually of salivary gland origin, has a signature v-myb avian myeloblastosis viral oncogene homolog-nuclear factor I/B (MYB-NFIB) gene fusion that activates MYB transcriptional regulatory activity. A new study in this issue by Stephens et al. is a comprehensive genomic mutation profiling analysis of this neoplasm and documents a common theme of alteration in chromatin regulatory genes. Also, mutations in SPEN (split ends, homolog of Drosophila), which encodes an RNA-binding coregulatory protein, suggest that other changes in transcriptional regulation may involve the NOTCH, FGFR, or other signaling pathways in which SPEN participates. Since there is a low prevalence of mutations in common oncogenes and tumor-suppressor genes, it is likely that alterations primarily in specific transcriptional regulatory genes, augmented by changes in chromatin structure, drive the neoplastic process in ACC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available